Silexion Therapeutics Reports First Quarter 2026 Financial Results

Silexion Therapeutics Corp. reported financial results for the three months ended March 31, 2026, and provided updates on its clinical development program. The company received approval from the Israeli Ministry of Health on March 24, 2026, to begin a Phase 2/3 clinical trial of SIL204 for locally advanced pancreatic cancer.

A Clinical Trial Application was submitted to Germany on April 28, 2026, through the EU Clinical Trials Information System.

It will start with a safety run-in cohort of approximately 18 patients, followed by a randomized cohort of approximately 166 patients. The trial will evaluate SIL204 in combination with standard chemotherapy using a dual-route administration approach that targets both primary tumors and metastatic disease.

Research and development expenses for the quarter totaled approximately $1.4 million, up 133.3% from $0.6 million in the same period of 2025. General and administrative expenses rose 27.3% to approximately $1.4 million from $1.1 million a year earlier.

Net loss for the quarter increased 58.8% to approximately $2.7 million from $1.7 million in the prior-year period. Cash and cash equivalents stood at $2.4 million as of March 31, 2026, down from $6.0 million at the end of 2025. Subsequent to quarter end, the company completed a warrant exercise inducement transaction that generated approximately $1.0 million in gross proceeds and raised additional capital through its at-the-market facility.